Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer: Is Sarcopenia Correlated with Postoperative Complications and Prognosis?

Hiroshi Saeki, Yuichiro Nakashima, Kensuke Kudou, Shun Sasaki, Tomoko Jogo, Kosuke Hirose, Keitaro Edahiro, Shotaro Korehisa, Daisuke Taniguchi, Ryota Nakanishi, Nobuhide Kubo, Koji Ando, Akira Kabashima, Eiji Oki, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

3 引用 (Scopus)

抄録

Background: Since the clinical impact of sarcopenia on multimodal therapy for patients with esophageal cancer is not well understood, this study was conducted to determine the influence of sarcopenia on the efficacy of neoadjuvant chemoradiotherapy (NACRT) for locally advanced esophageal cancer. Methods: The skeletal muscle index was quantified at the level of the third lumbar vertebra on computed tomography images, and sarcopenia was defined as a skeletal muscle index that was less than the average for each gender. We compared treatment outcomes in patients with cT3 and nearly T4 thoracic esophageal squamous cell carcinoma between the sarcopenia group (n = 85) and the non-sarcopenia group (n = 72). Results: The 5-year survival rates were 33.4% in the non-sarcopenia group and 31.5% in the sarcopenia group; these differences were not significant. The prognosis of the patients with sarcopenia was worse than that of the patients without sarcopenia in the surgery-alone group, but there was no difference between patients with and without sarcopenia in the NACRT group. Conclusions: NACRT could be a useful option for patients with locally advanced esophageal squamous cell carcinoma, even for those with sarcopenia, without increasing the incidence of morbidity and mortality.

元の言語英語
ページ(範囲)2894-2901
ページ数8
ジャーナルWorld journal of surgery
42
発行部数9
DOI
出版物ステータス出版済み - 9 1 2018

Fingerprint

Sarcopenia
Chemoradiotherapy
Esophageal Neoplasms
Skeletal Muscle
Lumbar Vertebrae
Thorax
Survival Rate
Tomography
Morbidity

All Science Journal Classification (ASJC) codes

  • Surgery

これを引用

Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer : Is Sarcopenia Correlated with Postoperative Complications and Prognosis? / Saeki, Hiroshi; Nakashima, Yuichiro; Kudou, Kensuke; Sasaki, Shun; Jogo, Tomoko; Hirose, Kosuke; Edahiro, Keitaro; Korehisa, Shotaro; Taniguchi, Daisuke; Nakanishi, Ryota; Kubo, Nobuhide; Ando, Koji; Kabashima, Akira; Oki, Eiji; Maehara, Yoshihiko.

:: World journal of surgery, 巻 42, 番号 9, 01.09.2018, p. 2894-2901.

研究成果: ジャーナルへの寄稿記事

Saeki, H, Nakashima, Y, Kudou, K, Sasaki, S, Jogo, T, Hirose, K, Edahiro, K, Korehisa, S, Taniguchi, D, Nakanishi, R, Kubo, N, Ando, K, Kabashima, A, Oki, E & Maehara, Y 2018, 'Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer: Is Sarcopenia Correlated with Postoperative Complications and Prognosis?', World journal of surgery, 巻. 42, 番号 9, pp. 2894-2901. https://doi.org/10.1007/s00268-018-4554-5
Saeki, Hiroshi ; Nakashima, Yuichiro ; Kudou, Kensuke ; Sasaki, Shun ; Jogo, Tomoko ; Hirose, Kosuke ; Edahiro, Keitaro ; Korehisa, Shotaro ; Taniguchi, Daisuke ; Nakanishi, Ryota ; Kubo, Nobuhide ; Ando, Koji ; Kabashima, Akira ; Oki, Eiji ; Maehara, Yoshihiko. / Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer : Is Sarcopenia Correlated with Postoperative Complications and Prognosis?. :: World journal of surgery. 2018 ; 巻 42, 番号 9. pp. 2894-2901.
@article{24236a4572944495aea58d0161a8047f,
title = "Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer: Is Sarcopenia Correlated with Postoperative Complications and Prognosis?",
abstract = "Background: Since the clinical impact of sarcopenia on multimodal therapy for patients with esophageal cancer is not well understood, this study was conducted to determine the influence of sarcopenia on the efficacy of neoadjuvant chemoradiotherapy (NACRT) for locally advanced esophageal cancer. Methods: The skeletal muscle index was quantified at the level of the third lumbar vertebra on computed tomography images, and sarcopenia was defined as a skeletal muscle index that was less than the average for each gender. We compared treatment outcomes in patients with cT3 and nearly T4 thoracic esophageal squamous cell carcinoma between the sarcopenia group (n = 85) and the non-sarcopenia group (n = 72). Results: The 5-year survival rates were 33.4{\%} in the non-sarcopenia group and 31.5{\%} in the sarcopenia group; these differences were not significant. The prognosis of the patients with sarcopenia was worse than that of the patients without sarcopenia in the surgery-alone group, but there was no difference between patients with and without sarcopenia in the NACRT group. Conclusions: NACRT could be a useful option for patients with locally advanced esophageal squamous cell carcinoma, even for those with sarcopenia, without increasing the incidence of morbidity and mortality.",
author = "Hiroshi Saeki and Yuichiro Nakashima and Kensuke Kudou and Shun Sasaki and Tomoko Jogo and Kosuke Hirose and Keitaro Edahiro and Shotaro Korehisa and Daisuke Taniguchi and Ryota Nakanishi and Nobuhide Kubo and Koji Ando and Akira Kabashima and Eiji Oki and Yoshihiko Maehara",
year = "2018",
month = "9",
day = "1",
doi = "10.1007/s00268-018-4554-5",
language = "English",
volume = "42",
pages = "2894--2901",
journal = "World Journal of Surgery",
issn = "0364-2313",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer

T2 - Is Sarcopenia Correlated with Postoperative Complications and Prognosis?

AU - Saeki, Hiroshi

AU - Nakashima, Yuichiro

AU - Kudou, Kensuke

AU - Sasaki, Shun

AU - Jogo, Tomoko

AU - Hirose, Kosuke

AU - Edahiro, Keitaro

AU - Korehisa, Shotaro

AU - Taniguchi, Daisuke

AU - Nakanishi, Ryota

AU - Kubo, Nobuhide

AU - Ando, Koji

AU - Kabashima, Akira

AU - Oki, Eiji

AU - Maehara, Yoshihiko

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background: Since the clinical impact of sarcopenia on multimodal therapy for patients with esophageal cancer is not well understood, this study was conducted to determine the influence of sarcopenia on the efficacy of neoadjuvant chemoradiotherapy (NACRT) for locally advanced esophageal cancer. Methods: The skeletal muscle index was quantified at the level of the third lumbar vertebra on computed tomography images, and sarcopenia was defined as a skeletal muscle index that was less than the average for each gender. We compared treatment outcomes in patients with cT3 and nearly T4 thoracic esophageal squamous cell carcinoma between the sarcopenia group (n = 85) and the non-sarcopenia group (n = 72). Results: The 5-year survival rates were 33.4% in the non-sarcopenia group and 31.5% in the sarcopenia group; these differences were not significant. The prognosis of the patients with sarcopenia was worse than that of the patients without sarcopenia in the surgery-alone group, but there was no difference between patients with and without sarcopenia in the NACRT group. Conclusions: NACRT could be a useful option for patients with locally advanced esophageal squamous cell carcinoma, even for those with sarcopenia, without increasing the incidence of morbidity and mortality.

AB - Background: Since the clinical impact of sarcopenia on multimodal therapy for patients with esophageal cancer is not well understood, this study was conducted to determine the influence of sarcopenia on the efficacy of neoadjuvant chemoradiotherapy (NACRT) for locally advanced esophageal cancer. Methods: The skeletal muscle index was quantified at the level of the third lumbar vertebra on computed tomography images, and sarcopenia was defined as a skeletal muscle index that was less than the average for each gender. We compared treatment outcomes in patients with cT3 and nearly T4 thoracic esophageal squamous cell carcinoma between the sarcopenia group (n = 85) and the non-sarcopenia group (n = 72). Results: The 5-year survival rates were 33.4% in the non-sarcopenia group and 31.5% in the sarcopenia group; these differences were not significant. The prognosis of the patients with sarcopenia was worse than that of the patients without sarcopenia in the surgery-alone group, but there was no difference between patients with and without sarcopenia in the NACRT group. Conclusions: NACRT could be a useful option for patients with locally advanced esophageal squamous cell carcinoma, even for those with sarcopenia, without increasing the incidence of morbidity and mortality.

UR - http://www.scopus.com/inward/record.url?scp=85042622220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042622220&partnerID=8YFLogxK

U2 - 10.1007/s00268-018-4554-5

DO - 10.1007/s00268-018-4554-5

M3 - Article

C2 - 29488065

AN - SCOPUS:85042622220

VL - 42

SP - 2894

EP - 2901

JO - World Journal of Surgery

JF - World Journal of Surgery

SN - 0364-2313

IS - 9

ER -